Idorsia Ltd (SWX:IDIA)

Market Cap	798.54M
Revenue (ttm)	217.22M
Net Income (ttm)	-133.30M
Shares Out	209.32M
EPS (ttm)	-0.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,214,827
Average Volume	2,286,925
Open	3.840
Previous Close	3.815
Day's Range	3.830 - 4.350
52-Week Range	0.612 - 4.350
Beta	1.51
RSI	71.43
Earnings Date	Oct 30, 2025

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 650
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: IDIA

Financial Performance

In 2024, Idorsia's revenue was 112.51 million, a decrease of -26.17% compared to the previous year's 152.39 million. Losses were -263.76 million, -11.47% less than in 2023.